News

Applied Therapeutics announced topline results from ARISE-HF on January 04, 2023 and plans to present full results at an upcoming medical conference.

These findings may require further evaluation using classification of age range as well as severity of disease, allowing for more precise results.

A study demonstrated olanzapine and samidorphan’s (LYBALVI) safety, tolerability, and durability during a 4-yeat treatment period.

The post-hoc analysis of the phase 3 ENHANCE study provides the first published evidence of a correlation between decreases in IL-31, bile acids, and pruritus symptoms in PBC following treatment with an investigational agent.

A new study identified T1D as a risk factor associated with nearly all subtypes of CHD, whereas overweight was associated only with certain defect types.

The FDA decision on berdazimer gel, 10.3%, represents the second approved treatment for the viral-borne skin disease.

In this episode, hosts breakdown as pair of recent studies examining management of diabetes during pregnancy.

These data on PMF among coal miners suggest that urgent action may need to be taken to protect these workers from the preventable disease.

For the first time, the FDA has approved a plan allowing Florida to import certain, cheaper prescription drugs from Canada.

Patients with lean NAFLD had fewer metabolic comorbidities but maintained similar risk of NASH, cirrhosis, nonliver cancer, and mortality compared to their overweight and obese counterparts.

Despite these findings, the study highlights the need for a careful decision on the use of lung biopsy in older children given both benefits and risks.

A new study found individuals with anorexia nervosa were associated with having a morning chronotype and vice versa.

We sat down with Tatyana Kushner, MD, BSCE to discuss findings from her study comparing IVF treatment in women with and without liver disease.

A new cohort study in China reports suggests the structure of green space decreased the relative risk of myopia among school-aged children.

A retrospective cohort study showed patients with Alzheimer disease treated with AChEIs had a slightly lower risk of incident AMD compared with untreated patients.

The December 2023 month in review for dermatology covers major stories regarding a new FDA approval, several new treatment findings, and news on attitudes toward those with acne.

Our endocrinology month in review spotlights our most popular content from December 2023. Our list of the most popular content from the past month includes the ADA Standards of Care—2024, label updates, a feature from our This Year in Medicine series, and more!

In a new study, hearing loss was significantly associated with a 7% higher risk of dementia, while hearing aids were shown to reduce such risks.

Our December 2023 month in review highlights top news in HCV screening, treatment with DAAs, and MASLD risk factors.

Twice-daily PDE4-inhibition using 10–40 mg of orismilast showed promise though further studies may be necessary to validate these findings.

A new study found smoking affects serum leptin levels for patients with obstructive sleep apnea on positive airway pressure therapy. Serum leptin levels increased in 40% of active smokers with obstructive sleep apnea but did not increase in any of the non-smokers.

Compared to nonusers, patients with type 2 diabetes and acute kidney disease administered SGLT-2is had a significantly lower risk of mortality, major adverse kidney events, and major adverse cardiovascular events.

The biosimilars month in review highlights interviews with experts discussing the cost-saving potential of increased biosimilars uptake in the US, a recent US Food and Drug Administration (FDA) approval, and the impact of a mandatory switch to an adalimumab biosimilar in New Zealand.

A case-control analysis shows the majority of autoimmune diseases demonstrate no effect on the development of new-onset age-related macular degeneration.

A systematic review combined with a pair of case studies suggest men who discontinue the front-line treatment for conditions like polycythaemia vera may improve their fertility.

Efficacy, pharmacokinetics, immunogenicity, and safety were comparable between patients receiving the aflibercept biosimilar SB15 and the reference drug.

Each month, our editorial staff compiles a recap of the top news in ophthalmology. Our December 2023 month-in-review features a recap of This Year in Medicine, the latest updates to the ophthalmic pipeline, and the newest episode of our KOL-led podcast series.

These data expand upon the limited literature available around the world regarding this inflammatory skin disorder.